Company intelligence / Profile preview

D16 Pharma & Biotec

Ownership: Private
Development stage: Other

Overview

D16 Pharma & Biotec is a Bangladesh-based pharmaceutical and biotech manufacturer with commercial operations. The company sponsored at least one Phase 4b clinical trial comparing two doses of rosuvastatin for hypercholesterolemia. No evidence was found for proprietary new molecular entities or advanced platform technologies. The company appears to focus on manufacturing, marketing, and local commercialization of established pharmaceuticals.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

UniMed UniHealth Pharmaceuticals Ltd.

Beyond the preview

Go deeper on D16 Pharma & Biotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D16 Pharma & Biotec.

Explore the full profile